



China, People's Republic of: Strengthening Healthcare Industry Development in Beijing-Tianjin-Hebei

Project Name	Strengthening Healthcare Industry Development in Beijing-Tianjin-Hebei	
Project Number	54039-001	
Country	China, People's Republic of	
Project Status	Proposed	
Project Type / Modality of Assistance	Technical Assistance	
Source of Funding / Amount	TA: Strengthening Healthcare Industry Development in Beijing-Tianjin-Hebei	
	Technical Assistance Special Fund	US\$ 300,000.00
Strategic Agendas	Inclusive economic growth	
Drivers of Change	Governance and capacity development Knowledge solutions Private sector development	
Sector / Subsector	Health - Health system development	
Gender Equity and Mainstreaming	Some gender elements	
Description	Strengthening of the healthcare industry in BTH can improve the regions' capacity to respond to the coronavirus disease (COVID-19) pandemic, through the provision of the required health equipment and development of a potential COVID-19 vaccine. The purpose, focus, or emphasis of this TA is to develop evidence-based strategies and policies to strengthen the healthcare industry in circum-Beijing (BTH). The TA will address the lack of coordination, industrial agglomeration, underdeveloped supply chains, and lack of innovation in the healthcare industry through (i) assessment of the industry policies, guidelines, and regulations; (ii) strengthening the healthcare industry coordination capacity; and (iii) dissemination of knowledge and lessons learned to policymakers	
Project Rationale and Linkage to Country/Regional Strategy	Although the PRC's healthcare industry is one of the world's largest, most pharmaceutical sales are domestic with 80% of the market focused on low cost generic drugs and 20% on patented drugs which are mostly imported. The generic drugs are largely purchased by public hospitals and pharmacies for consumption by the PRC's more than 1.3 billion population, accounting for a significant proportion of the PRC's state health budget. The PRC is also a major global producer of active pharmaceutical ingredients and basic chemicals required to develop more complex finished pharmaceutical products. However, exports of finished pharmaceutical products are less significant. Around 97% of drugs sold by local Chinese manufacturers are generic. Despite its well-developed domestic pharmaceutical manufacturing sector, the PRC is a major importer of internationally developed pharmaceutical products. As these imported products are patent-protected and more expensive, a substantial part of the PRC's medicines budget is spent on imported drugs. The PRC lacks development of innovative, high quality 'blockbuster' drugs, and vaccines that can both cater to the needs of the domestic market and can be exported in the region, and globally.	
Impact	Healthcare industry in BTH region strengthened	
Outcome	Policy coordination and development of the healthcare industry improved	
Outputs	BTH healthcare industry policies, regulations and guidelines, and markets assessed Health industry coordination and innovation capacity strengthened Knowledge and lessons learned disseminated	
Geographical Location	Nation-wide, Beijing, Beijing, Hebei, Tianjin	
Summary of Environmental and Social Aspects		
Environmental Aspects		
Involuntary Resettlement		
Indigenous Peoples		
Stakeholder Communication, Participation, and Consultation		
During Project Design		
During Project Implementation		
Business Opportunities		
Consulting Services	The Hebei Provincial Finance Department will be the executing agency and the Hebei Institute of Fiscal Sciences and Policy will be the implementing agency of the TA. ADB will administer the TA, engage a consulting firm and an individual consultant, and carry out procurement following the ADB Procurement Policy (2017, as amended from time to time) and its associated procurement staff instructions.	
Responsible ADB Officer	Habib, Najibullah	
Responsible ADB Department	East Asia Department	

Responsible ADB Division	Urban and Social Sectors Division, EARD
Executing Agencies	Hebei Provincial Finance Department 48 South Zhonghua Street

Timetable	
Concept Clearance	30 Oct 2020
Fact Finding	28 Aug 2020 to 31 Aug 2020
MRM	-
Approval	-
Last Review Mission	-
Last PDS Update	04 Nov 2020

Project Page	https://www.adb.org/projects/54039-001/main
Request for Information	http://www.adb.org/forms/request-information-form?subject=54039-001
Date Generated	06 November 2020

ADB provides the information contained in this project data sheet (PDS) solely as a resource for its users without any form of assurance. Whilst ADB tries to provide high quality content, the information are provided "as is" without warranty of any kind, either express or implied, including without limitation warranties of merchantability, fitness for a particular purpose, and non-infringement. ADB specifically does not make any warranties or representations as to the accuracy or completeness of any such information.